Carol Aghajanian

ORCID: 0000-0003-0851-3225 · 2 papers in corpus

other 2023

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283

Gynecologic Oncology ·doi:10.1016/j.ygyno.2023.06.021

OBJECTIVE: Gynecologic cancers are traditionally managed according to their presumed site of origin, without regard to the underlying histologic subtype. Clear cell histology is associated with chemotherapy refractoriness and poor survival.…

article 2016

Utilization of an institutional algorithm for fertility preservation in young women with endometrial cancer

·doi:10.1016/j.ygyno.2016.04.328